BPC-157: benefits, uses, safety & what the research shows

By Kokei Abam, RDN · Registered Dietitian Nutritionist

Published October 21, 2026 · Last reviewed November 2, 2026 · 16 min read

BPC-157 (body protection compound 157) is a synthetic 15-amino-acid peptide based on a sequence from a protein found in human gastric juice. After demonstrating tissue-repair effects in animal studies, BPC-157 has gained popularity for its purported benefits in injury recovery, pain relief, and gut healing. However, most evidence comes from laboratory and animal research, while published human studies remain small and preliminary, leaving its clinical benefits and safety unestablished. A controlled clinical trial is underway, but BPC-157 is not FDA-approved for any medical use. In 2026, the FDA removed BPC-157 from Category 2, its list of bulk substances flagged for significant compounding safety concerns. Removal did not establish its safety or make it legal to compound.¹

What is BPC-157?

BPC-157 is a synthetic peptide composed of 15 amino acids. It was developed from research into a body protection compound (BPC), a protein identified in human gastric juice. Also known as gastric pentadecapeptide, Bepecin, PL-14736, PL-10, and PLD-116, it has been investigated for its potential tissue-protective and healing effects, although its clinical benefits in humans remain unestablished.

The FDA records distinguish between two chemical forms of BPC-157: the free base and the acetate salt. The free base is the peptide in its non-salt form. In the acetate form, acetate ions derived from acetic acid are associated with the peptide to form a salt. Neither form is FDA-approved for medical use.³

Why is BPC-157 so popular?

BPC-157 has attracted interest among athletes and people seeking faster recovery from injuries, partly because animal studies suggest potential tissue-healing effects. When Vasireddi et al. did a systematic review in 2025, they identified 36 studies consisting of 35 preclinical studies and one clinical study. In those studies, animal models showed improved healing outcomes in muscle, tendon, ligament, and bone injuries, but human evidence remained limited.⁴

The "Wolverine Stack" is another reason BPC-157 has been popular. It is a combination of BPC-157 and TB-500 marketed in fitness and peptide communities for injury recovery. TB-500 is a synthetic peptide based on thymosin beta-4, a protein involved in cellular processes linked to tissue repair. Despite these factors, clinical evidence has not established the effectiveness of this combination.

A September 2026 preprint by Venkatakrishnan et al. offers further insight into BPC-157's growing use. Analyzing clinical notes from a US healthcare network, researchers identified 1,039 patients with documented use between 2020 and 2026. The quarterly number of newly confirmed users increased 33-fold. Pain was documented in 33% of users, gastrointestinal conditions in 14%, previous injuries in 11%, and post-surgical healing in 10%. Among 354 patients whose records documented the direction of their response, 79% had symptomatic improvement recorded.⁵

These findings document growing use and reported improvement, but the uncontrolled study cannot establish that BPC-157 caused those outcomes. Its popularity reflects interest in its potential healing effects, while definitive evidence of clinical benefit remains lacking.

How might BPC-157 work?

BPC-157 may influence tissue repair by affecting blood-vessel function and the behavior of cells involved in healing, potentially improving blood supply to injured tissue and helping repair cells move into it. Preclinical evidence points to changes in vascular signaling and fibroblast activity, although the molecular target that initiates these effects remains unidentified.

One proposed pathway involves vascular endothelial growth factor receptor 2 (VEGFR2), which regulates endothelial-cell growth and migration during new blood-vessel formation. Hsieh et al. (2017) found that BPC-157 increased VEGFR2 expression and activated downstream Akt–endothelial nitric oxide synthase (eNOS) signaling in cultured human endothelial cells.⁶ In experimental models, the researchers also observed increased vessel density and improved blood-flow recovery in rats with hindlimb ischemia.

Nitric oxide (NO) helps relax blood vessels and maintain circulation. Its production by endothelial nitric oxide synthase (eNOS) is regulated by caveolin-1, which inhibits eNOS through direct binding. Hsieh et al. (2020) found that BPC-157 altered Src–Caveolin-1–eNOS signaling and reduced the binding between caveolin-1 and eNOS in cultured endothelial cells, suggesting a potential mechanism for increased NO production. Experiments using isolated rat aortas further implicated NO signaling in the vasodilation observed with BPC-157.⁷

The evidence for increased blood-vessel formation is less consistent across experimental systems. In Brcic et al. (2009), BPC-157 showed no direct angiogenic effects in cell culture, despite changes in VEGF expression and blood-vessel formation markers during muscle and tendon healing in rats.⁸ This suggests that its effects on blood-vessel formation may depend on the tissue environment, although the reasons remain unclear.

BPC-157 has also been investigated for its effects on fibroblasts, which produce and organize components of the extracellular matrix during tissue repair. Chang et al. (2011) found that the peptide increased phosphorylation of focal adhesion kinase (FAK) and paxillin, proteins involved in cell attachment and movement, in cultured rat tendon fibroblasts.⁹ The cells showed greater migration and spreading and survived oxidative stress better. Proliferation did not increase directly.

Another proposed pathway involves growth hormone signaling. Chang et al. (2014) found increased growth hormone receptor expression in cultured rat tendon fibroblasts following BPC-157 exposure. Subsequent growth hormone exposure activated Janus kinase 2 (JAK2), a protein involved in receptor signaling.¹⁰ Greater receptor expression could make fibroblasts more responsive to growth hormone, but whether this contributes meaningfully to tissue repair in living organisms remains uncertain.

These findings offer possible explanations for BPC-157's effects in experimental models, but they do not establish how the peptide works in humans.

What has BPC-157 been studied for?

Researchers have studied BPC-157 in animal models of tissue injury and disease, with limited research in humans. The table summarizes the main areas investigated and the evidence available.

Area studied	Animal and laboratory evidence	Human evidence	Evidence tier
Musculoskeletal injuries (tendons, ligaments, muscles, bones)	Achilles tendon healing (Staresinic et al., 2003); tendon-cell survival and migration (Chang et al., 2011); muscle and tendon angiogenesis (Brcic et al., 2009). Ligament and bone studies reviewed by Vasireddi et al. (2025).	Subjective improvement in a retrospective knee-pain study (Lee & Padgett, 2021). A Phase 2 hamstring-strain trial is recruiting; results unavailable.	Experimental
Gastrointestinal conditions (ulcers, colitis)	Gastric ulcer models (Xue et al., 2004); rat models of colitis and ischemia–reperfusion injury (Duzel et al., 2017).	Historical placebo-controlled ulcerative colitis study involving 53 participants; available details are insufficient to establish efficacy (FDA, 2026).	Experimental
Bladder conditions (interstitial cystitis)	Limited	Symptom improvement reported in an uncontrolled 12-person pilot study (Lee et al., 2024).	Experimental
Wound healing and organ injury	Preclinical safety evaluation for potential wound treatment (Xu et al., 2020); effects in rat ischemia–reperfusion models (Duzel et al., 2017).	Human efficacy for wound healing or organ protection has not been established.	Experimental

What does human research actually show?

Human evidence for BPC-157 comes mainly from small clinical reports and incompletely documented historical trial data. Although patients have reported symptom improvement, the available evidence does not establish that BPC-157 caused it. A historical controlled study remains difficult to evaluate, and a registered Phase 2 trial has yet to report results.

Lee and Padgett (2021) retrospectively reviewed 17 patients treated with intra-articular BPC-157 for knee pain. Of the 16 reached for follow-up, 11 of 12 receiving BPC-157 alone and three of four receiving it with thymosin beta-4 reported significant improvement.¹¹

Lee et al. (2024) administered 10 mg of BPC-157 around inflamed bladder tissue in 12 women with interstitial cystitis. Ten reported complete symptom resolution, and two reported 80% improvement. No adverse events were reported.¹² The subjective assessments, small sample, and lack of a comparison group prevent reliable conclusions about efficacy.

Lee and Burgess (2025) administered intravenous BPC-157 to two previously exposed participants at 10 mg on day one and 20 mg on day two.¹³ No adverse effects or measurable changes in selected biomarkers were reported through day three, providing little information about longer-term safety or use in new patients.

The FDA's July 2026 briefing reviewed historical data that included a reported randomized, placebo-controlled study of 53 people with mild-to-moderate ulcerative colitis. Participants received daily BPC-157 enemas or placebo for two weeks, and disease activity reportedly improved.³ The available information is insufficient to assess the findings' reliability or establish efficacy.

Historical Phase 1 data reviewed by the FDA describe rectal BPC-157 administration in healthy volunteers, although the available documentation provides limited detail. Human research has also included a separate Phase 1 trial of oral BPC-157 (ClinicalTrials.gov, NCT02637284), designed to assess safety and pharmacokinetics; however, no results are posted in the trial registry, and the relationship between the two studies remains unclear.³

The FDA briefing lists three adverse-event reports associated with BPC-157-containing products: injection-site reactions, shortness of breath requiring emergency care, and skin or gum pigmentation changes. These reports do not establish causation. The FDA concluded that the available information was insufficient to characterize BPC-157's safety profile.³

As of November 2026, the BPC-HAMSTR trial is recruiting participants for a Phase 2 study of BPC-157 in acute hamstring injuries. The randomized, placebo-controlled, quadruple-masked trial plans to enroll 120 people with MRI-confirmed grade II hamstring strains. Participants receive daily subcutaneous BPC-157 or placebo for 14 days alongside standardized rehabilitation. The primary outcomes include time to return to unrestricted sport and MRI-measured injury volume. No results have been posted.¹⁴

Venkatakrishnan et al. (2026) analyzed clinical notes for 1,039 confirmed BPC-157 users in a US electronic health record network. In this preprint, which has not undergone peer review, newly identified users per quarter increased from four in early 2020 to 134 in early 2026. Response direction was documented for 354 users: 279 improved, 58 were unchanged, and 17 worsened. For the remaining 685 users, about two-thirds of the total, the records did not establish the direction of response.¹⁵ The absence of a comparison group prevents attribution of these outcomes to BPC-157. Adverse-event signals involving neuropsychiatric symptoms, injection-site hypersensitivity, and gastrointestinal symptoms were also reported, although likely underreporting and the observational design limit interpretation.

Józwiak et al. (2025) found that more than 80% of BPC-157 records in a PubMed search conducted on May 20, 2025, had P. Sikiric or S. Seiwerth as first or senior author. They also noted that studies frequently used a single dose, limiting dose–response assessment.¹⁶ Independent replication and studies comparing multiple doses are needed to assess reproducibility and clarify dose-dependent effects.

Potential benefits: what is plausible vs. proven?

Tendon healing and tissue repair. In a rat model of Achilles tendon injury, Staresinic et al. (2003) found that BPC-157 treatment improved tendon strength, functional outcomes, and histological features of healing.¹⁷ Chang et al. (2011) also reported increased tendon-cell migration and survival in laboratory experiments.⁹

Gastrointestinal protection. Xue et al. (2004) found fewer gastric ulcer lesions in rats treated with BPC-157.¹⁸ In subsequent animal experiments, Duzel et al. (2017) reported protection of intestinal mucosal tissue in models of colitis and ischemia-reperfusion injury.¹⁹

Knee pain. In a retrospective chart review, Lee and Padgett (2021) reported pain improvement in 11 of 12 patients who received intra-articular BPC-157 for knee pain.¹¹ The absence of a control group limits how much we can attribute these improvements to the peptide.

Interstitial cystitis. Lee et al. (2024) reported complete symptom resolution in 10 of 12 women treated with BPC-157, while the other two reported an 80% improvement.¹² The uncontrolled design limits interpretation.

Short-term tolerability. Lee and Burgess (2025) observed no adverse effects during short-term monitoring of two participants who received intravenous BPC-157.¹³ The sample size and brief follow-up provide little information about uncommon or delayed adverse effects.

What are the side effects of BPC-157, and is it safe?

BPC-157 is not FDA-approved for human use, and there is insufficient clinical evidence to establish its safety or determine the frequency of potential side effects. The available human data are too limited to assess the risks of prolonged use.

The FDA's July 2026 review identified three adverse-event reports following BPC-157 injections. Reported events included injection-site redness and swelling, shortness of breath requiring emergency care, and skin and gum darkening in a person using BPC-157 with TB-500. The darkening reportedly recurred upon re-exposure. These reports alone cannot establish that BPC-157 itself caused the events, particularly in the case involving combined use with TB-500.³

Xu et al. (2020) evaluated the peptide in preclinical studies, and the FDA's subsequent review reported changes in blood-clotting measures and laboratory markers associated with liver function in rats and dogs after 28 days of intramuscular administration.^3,20 These findings identify potential safety signals in animals, but their relevance to human use remains undetermined. Longer-term repeat-dose animal data were unavailable.

The FDA has additionally raised concerns about possible immune reactions associated with peptide-related impurities and aggregation.²¹ Products sold online as "research use only" may also have unverified identity, purity, concentration, and sterility, making their safety difficult to assess.

Is BPC-157 FDA-approved or legal to compound?

BPC-157 is not FDA-approved for human use. Its regulatory status also affects whether a compounding pharmacy can legally prepare it. To understand the current position, it helps to distinguish FDA drug approval from the rules governing compounded medications. For the broader framework, see our peptide therapy overview.

What does FDA drug approval mean?

FDA drug approval means the agency has reviewed evidence of a drug's safety and effectiveness for its intended use, along with its manufacturing quality, and determined that it meets the requirements for approval. BPC-157 is not FDA-approved for human use.

What is Category 2?

Category 2 was part of the FDA's interim policy for bulk drug substances nominated for compounding under Section 503A. It identified substances that the FDA considered to raise significant safety concerns. BPC-157 was removed from Category 2 in April 2026 after its nominations were withdrawn. Removal did not establish its safety or authorize its use in compounded medications.²¹

What is the 503A Bulks List?

Section 503A of the Federal Food, Drug, and Cosmetic Act sets conditions under which pharmacies and other qualified practitioners may compound medications for individual patients. The FDA's 503A Bulks List identifies bulk drug substances that may be used for compounding under the applicable legal requirements. Inclusion on the list does not constitute FDA approval of a drug. BPC-157 is not currently on the 503A Bulks List.

BPC-157's regulatory timeline

On September 29, 2023, the FDA placed BPC-157 in Category 2 under its interim compounding policy. The agency cited potential immune reactions associated with certain routes of administration, concerns about peptide-related impurities, difficulties characterizing the active ingredient, and insufficient safety information to determine whether the substance could cause harm in humans.

In April 2026, the FDA removed BPC-157 from Category 2 after its nomination was withdrawn. The substance appeared on the agency's list of withdrawn nominations, where its safety concerns remained documented. Removal from Category 2 did not place BPC-157 in Category 1 or add it to the 503A Bulks List.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee considered BPC-157 free base and BPC-157 acetate for potential inclusion on the 503A Bulks List for ulcerative colitis. FDA staff recommended against adding either form. The committee voted 8–6, with one abstention, to recommend adding both forms.³

The committee's recommendation was non-binding. It did not approve BPC-157 as a drug or authorize compounding for ulcerative colitis, injury recovery, or general use. The FDA retains responsibility for the final regulatory decision.

On October 15, 2026, the FDA and the Department of Health and Human Services submitted a proposed Interim Access Policy for Compounding Using Certain Peptides to the White House Office of Management and Budget for review. Reuters reported that the proposal could facilitate temporary access to certain peptides, including BPC-157, through compounding.² The proposal's full text had not been made public at the time of reporting, and submission for review did not itself put the policy into effect.

Can pharmacies compound BPC-157 now?

As of November 2026, BPC-157 is not listed on the FDA's 503A Bulks List, and no final FDA decision adding either form has been published. The proposed interim access policy is a separate regulatory process; its submission alone does not authorize compounding.

The FDA does not approve dietary supplements before they are sold, and a supplement label does not make BPC-157 legal or safe to use. Products labeled "research use only" are not thereby approved for human use, and that label does not establish that their sale or intended use complies with applicable law.

BPC-157 and competitive sports

BPC-157 has attracted interest among athletes seeking faster recovery from sports-related injuries, particularly tendon, ligament, and muscle injuries. However, athletes considering the peptide must account for its anti-doping status before use.

The World Anti-Doping Agency (WADA) lists BPC-157 under S0, Non-Approved Substances, a category prohibited at all times, both in and out of competition, including during the off-season. WADA establishes the international framework for anti-doping rules, and its Prohibited List is implemented by signatories to the World Anti-Doping Code across many major sports worldwide.²²

Athletes competing in collegiate or professional leagues, or under military testing programs, should also check the specific rules governing their participation. Although many organizations follow WADA standards or maintain comparable restrictions, their policies and procedures may differ.

BPC-157 is prohibited both in competition and out of competition, including during the off-season. This restriction applies regardless of whether an athlete uses it for injury recovery or another purpose.

Questions to ask before considering BPC-157

If you are considering BPC-157, speaking with your physician first and using these questions to guide the discussion can help you make a more informed decision.

1. What evidence supports BPC-157 for my specific condition or treatment goal?
2. Are there FDA-approved treatments or other evidence-based alternatives for my condition?
3. What are the potential risks, including long-term uncertainties and interactions with my medications or existing health conditions?
4. What monitoring would I need, and what should I do if I experience an adverse reaction?
5. What is BPC-157's current regulatory status, and can the pharmacy or supplier legally provide it for my intended use?
6. Is the product BPC-157 free base or acetate, and does that distinction affect its regulatory status or available safety evidence?
7. If I compete in sports, does my governing body prohibit BPC-157, including during the off-season?

A registered dietitian's perspective on BPC-157

If you are considering BPC-157 for gastrointestinal concerns or injury recovery, I would first assess the underlying condition and the treatments supported by evidence for that specific indication. Depending on the diagnosis, I would consider appropriate medical care, targeted nutritional interventions, or structured rehabilitation, guided by the individual's needs and the available clinical evidence.

This approach would be my starting point, given the limited human evidence and unresolved safety concerns surrounding BPC-157, particularly in light of the FDA's concerns about potential immune reactions and insufficient information to determine its safety in humans. Establishing its clinical value would require well-designed human studies demonstrating reproducible benefits across patient populations and adequately assessing safety over time; such evidence remains insufficient as of November 2026.

My priority would be to identify the interventions with the strongest evidence for addressing the individual's condition and treatment goals before considering an experimental peptide whose benefits and risks remain insufficiently characterized.

Frequently asked questions

How long does BPC-157 take to work?

No controlled human study has established whether BPC-157 works or how long its effects might take to appear. Reported timelines are anecdotal. A registered Phase 2 trial for acute hamstring injuries may provide further evidence.

Is BPC-157 safe to use during pregnancy or breastfeeding?

BPC-157 has not been adequately studied in pregnant or breastfeeding women, so its safety in these circumstances is unknown. Consult your healthcare professional before considering its use.

Can BPC-157 interact with other medications or supplements?

Potential interactions between BPC-157 and medications or supplements have not been established in human studies. Tell your physician and pharmacist about all products you take before considering BPC-157.

Is BPC-157 the same as TB-500?

No. BPC-157 and TB-500 are distinct peptides with different structures.

Does health insurance cover BPC-157?

Health insurance generally does not cover BPC-157 because it is not an FDA-approved treatment. Contact your insurer to confirm your specific coverage.

Does a certificate of analysis prove a BPC-157 product is safe?

No. A certificate of analysis may confirm the identity and purity of the tested sample, but it does not establish human safety or sterility or guarantee that every vial matches the sample. Some certificates are issued by sellers rather than independent laboratories.

How do I report a side effect from BPC-157?

Contact your healthcare professional about suspected side effects and seek emergency care for serious reactions. You can also report suspected adverse events to the FDA through its MedWatch reporting program.

Related reading

Peptides

Peptide therapy: types, benefits, risks & what to know in 2026

FDA-approved medicines, compounded products, and investigational peptides — with the evidence graded honestly.

Peptides

PT-141: libido, sexual function, evidence & safety

The development name for bremelanotide — what the FDA-approved product can do, and what the compounded versions can't claim.

GLP-1

GLP-1 medications, explained clearly

Semaglutide, tirzepatide, and the whole class — the most-studied peptide medicines in modern practice.

← All articles